SEC Comment Letter 0000000000-23-012792 to Apellis Pharmaceuticals, Inc. (APLS) (CIK 0001492422) (APLS)

Apellis Pharmaceuticals, Inc. (APLS) (CIK 0001492422)
Date: Nov. 22, 2023 · CIK: 0001492422 · Accession: 0000000000-23-012792

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-38276

Date

November 22, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Apellis Pharmaceuticals, Inc. (APLS) (CIK 0001492422)

Letter

United States securities and exchange commission logo November 22, 2023 Timothy E. Sullivan Chief Financial Officer and Treasurer Apellis Pharmaceuticals, Inc. 100 Fifth Avenue Waltham, MA 02451 Re:Apellis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 21, 2023 Form 10-Q for the period ended September 30, 2023 Filed November 1, 2023 File No. 001-38276 Dear Timothy E. Sullivan: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
November 22, 2023
Timothy E. Sullivan
Chief Financial Officer and Treasurer
Apellis Pharmaceuticals, Inc.
100 Fifth Avenue
Waltham, MA 02451
Re:Apellis Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed February 21, 2023
Form 10-Q for the period ended September 30, 2023
Filed November 1, 2023
File No. 001-38276
Dear Timothy E. Sullivan:
            We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io